Patents Assigned to The Trustees of the University of Pennsylvania
  • Patent number: 10259849
    Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: April 16, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
  • Patent number: 10260065
    Abstract: This invention provides sets and libraries of short hairpin ribonucleic acid (shRNA) molecules comprising a double-stranded region of random sequence containing random mismatches, methods of generating same, sets and libraries of expression vectors for same, methods of generating same, and methods for identifying an RNA therapeutic or RNA molecule that has an ability to affect a biological parameter, for identifying a drug target for a disease or disorder of interest, and for identifying a variant of an RNA molecule that has an altered ability to affect a biological parameter of interest.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: April 16, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Robert B. Wilson, Yongping Wang
  • Publication number: 20190105396
    Abstract: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
    Type: Application
    Filed: October 29, 2018
    Publication date: April 11, 2019
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Steven Siegel, Karen WINEY
  • Publication number: 20190105225
    Abstract: An ambulatory respiratory assist device utilizes a cuirass worn on the chest and/or abdomen and supported by a hip belt so that it does not place a load on the patient's shoulders. The belt also supports a ventilator that includes a pump and its power supply, valving, controls and auxiliary equipment. The device is optionally integrated with auxiliary features such as chest wall vibration, which can be achieved by utilizing cuirass pressure modulation, with shoulder or upper arm supports for simulating the “tripod position”, with positive pressure ventilation apparatus, or with patient monitoring. Shoulder or upper arm supports can extend directly from the belt to the shoulders or upper arms, utilized independently of the cuirass, and optionally integrated with one or more of the above-mentioned auxiliary features.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 11, 2019
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Jacob Brenner, Christopher Polster, Michael Sims
  • Patent number: 10253086
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: April 9, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • Publication number: 20190099409
    Abstract: The invention includes methods, kits, and pharmaceutical compositions for enhancing liver regeneration in a mammal in need thereof, comprising administering a therapeutically effective amount of an agent that increases nicotinamide adenine dinucleotide (NAD) activity. The methods may include administering a therapeutically effective amount of an agent that increases nicotinamide adenine dinucleotide (NAD) activity and a sirtuin 1 (Sirt1) agonist. The agent that increases NAD activity may be a NAD precursor. The NAD precursor may include one or more of tryptophan, nicotinic acid, nicotinic acid riboside, nicotinamide riboside (NR), nicotinamide, NADP, and NAD itself and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 22, 2017
    Publication date: April 4, 2019
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Joseph BAUR, Sarmistha MUKHERJEE
  • Publication number: 20190099386
    Abstract: The invention relates to dezocine compositions and uses thereof. Specifically, the invention relates to dezocine compositions, including nano-dezocine compositions and methods for preventing or treating opioid receptor associated diseases, including neuropathic pain; addiction, such as opioid or cocaine addiction; and depression.
    Type: Application
    Filed: April 30, 2018
    Publication date: April 4, 2019
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Renyu Liu, Geoffrey Krug, Feixiang Wu, Julie Blendy
  • Patent number: 10245274
    Abstract: This invention relates a controlled release delivery composition for an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination, using a chitosan-glycerophosphate (CGP) hydrogel and an agent or a bio-materials. Additionally, provided methods of treating an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: April 2, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Bert W. O'Malley, Daqing Li, David Paulson
  • Patent number: 10245431
    Abstract: Provided is an implantable medical device for predicting and treating electrical disturbances in tissue. The medical device includes an implantable telemetry unit (ITU), and an implantable leads assembly including a first and a second electrode implanted in the tissue. A processor of the ITU is configured to perform training by receiving electrical signals input to the electrode circuit, parsing the electrical signals into dynamic event states using Bayesian Non-Parametric Markov Switching, and modeling each event state as a multi-dimensional probability distribution. The processor of the ITU is further configured to perform analysis of the electrical signals and therapy to the tissue by applying other electrical signals to the multi-dimensional distribution to predict future electrical disturbances in the tissue, and controlling the electrode circuit to apply an electrical therapy signal to the first and second electrodes to mitigate effects of the future electrical disturbances in the tissue.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: April 2, 2019
    Assignees: The Trustees of the University of Pennsylvania, University of Washington
    Inventors: Steven N. Baldassano, Brian Litt, Drausin Wulsin, Emily Fox
  • Publication number: 20190083470
    Abstract: The invention provides p38 MAPK inhibitors that compensate for a frataxin deficiency or mutation and methods of using the same (e.g., to treat Friedreich's ataxia).
    Type: Application
    Filed: March 23, 2016
    Publication date: March 21, 2019
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Robert B. Wilson
  • Patent number: 10232030
    Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV6 E6E7, HPV11 E6E7, HPV16 E6E7, HPV18 E6E7, HPV31 E6E7, HPV33 E6E7, HPV39 E6E7, HPV45 E6E7, HPV52 E6E7, and HPV58 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 19, 2019
    Assignees: INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Jian Yan
  • Patent number: 10233216
    Abstract: Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of IgE. Using murine and canine hemophilia as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of a coagulation factor expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated subjects when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after four to six exposures to intravenous coagulation factor protein.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: March 19, 2019
    Assignees: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Inc.
    Inventors: Roland W. Herzog, Henry Daniell
  • Patent number: 10232055
    Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 19, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Katalin Kariko, Drew Weissman
  • Patent number: 10233425
    Abstract: The invention includes compositions and methods to rapidly isolate and culture cells that are potent for use in adoptive immunotherapy. In one embodiment, the isolated cells of the invention are tumor infiltrating lymphocytes (TIL) that express CD137 (also known as 4-1BB and TNFSFR9).
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: March 19, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Daniel J. Powell, Jr.
  • Patent number: 10235754
    Abstract: A method is provided for measuring or estimating stress distributions on heart valve leaflets by obtaining three-dimensional images of the heart valve leaflets, segmenting the heart valve leaflets in the three-dimensional images by capturing locally varying thicknesses of the heart valve leaflets in three-dimensional image data to generate an image-derived patient-specific model of the heart valve leaflets, and applying the image-derived patient-specific model of the heart valve leaflets to a finite element analysis (FEA) algorithm to estimate stresses on the heart valve leaflets. The images of the heart valve leaflets may be obtained using real-time 3D transesophageal echocardiography (rt-3DTEE). Volumetric images of the mitral valve at mid-systole may be analyzed by user-initialized segmentation and 3D deformable modeling with continuous medial representation to obtain, a compact representation of shape.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: March 19, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Benjamin M. Jackson, Robert C. Gorman, Joseph H. Gorman, Alison M. Pouch, Chandra M. Sehgal, Paul A. Yushkevich, Brian B. Avants, Hongzhi Wang
  • Publication number: 20190077834
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 14, 2019
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Patent number: 10226528
    Abstract: Disclosed herein is a vaccine comprising an antigen and one or more bimolecular adjuvant. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 12, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Karuppiah Muthumani
  • Patent number: 10226526
    Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV39 E6E7 and HPV45 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: March 12, 2019
    Assignees: INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David Weiner, Jian Yan
  • Publication number: 20190070824
    Abstract: The presently disclosed subject matter relates to nanocardboard structures and methods of fabrication thereof. An exemplary nanocardboard structure includes at least two parallel planar films and webbing. The planar films can be separated from each other by a gap of from about 0.1 micrometers to about 1000 micrometers.
    Type: Application
    Filed: August 15, 2018
    Publication date: March 7, 2019
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Igor Bargatin, Chen Lin, Samuel Nicaise
  • Patent number: 10223139
    Abstract: CRYSTAL “Cognitive radio you share, trust and access locally” (CRYSTAL) is a virtualized cognitive access point that may provide for combining multiple wireless access applications on a single hardware platform. Radio technologies such as LTE, WiMax, GSM, and the like can be supported. CRYSTAL platforms can be aggregated and managed as a cloud, which provides a model for access point sharing, control, and management. CRYSTAL may be used for scenarios such as neighborhood spectrum management. CRYSTAL security features allow for home/residential as well as private infrastructure implementations.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 5, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jonathan M. Smith, Eric R. Keller, Thomas W. Rondeau, Kyle B. Super